Independent Review of Indonesian Phase 3 R327G Trial Data
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Patient recruitment and dosing are ongoing while the DMC prepares its recommendations, which are expected to be available following their meeting. The company will provide a market update after receiving the DMC's formal recommendations.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Notification regarding unquoted securities - RCE
- Amendments to Debt Facility with Avenue Capital Group
- Notice of Annual General Meeting/Proxy Form
- Notification of cessation of securities - RCE
- Resolutions under section 249N of the Corporations Act
Later from Recce Pharmaceuticals
- License and Commercialisation Agreement in AUS/NZ for R327G
- Quarterly Activities/Appendix 4C Cash Flow Report
- Application for quotation of securities - RCE
- Cleansing Notice
- Options Prospectus
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals